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Abstract
Background: Human immunodeficiency virus (HIV)-related chronic lung disease (CLD) among children is associated
with substantial morbidity, despite antiretroviral therapy. This may be a consequence of repeated respiratory tract
infections and/or dysregulated immune activation that accompanies HIV infection. Macrolides have anti-inflammatory
and antimicrobial properties, and we hypothesised that azithromycin would reduce decline in lung function and
morbidity through preventing respiratory tract infections and controlling systemic inflammation.
Methods/design: We are conducting a multicentre (Malawi and Zimbabwe), double-blind, randomised controlled trial
of a 12-month course of weekly azithromycin versus placebo. The primary outcome is the mean change in forced
expiratory volume in 1 second (FEV1) z-score at 12 months. Participants are followed up to 18 months to explore the
durability of effect. Secondary outcomes are FEV1 z-score at 18 months, time to death, time to first acute respiratory
exacerbation, number of exacerbations, number of hospitalisations, weight for age z-score at 12 and 18 months,
number of adverse events, number of malaria episodes, number of bloodstream Salmonella typhi infections and
number of gastroenteritis episodes. Participants will be followed up 3-monthly, and lung function will be assessed
every 6 months. Laboratory substudies will be done to investigate the impact of azithromycin on systemic inflammation
and on development of antimicrobial resistance as well as impact on the nasopharyngeal, lung and gut microbiome.
Discussion: The results of this trial will be of clinical relevance because there are no established guidelines on the
treatment and management of HIV-associated CLD in children in sub-Saharan Africa, where 80% of the world’s HIV-
infected children live and where HIV-associated CLD is highly prevalent.
Trial registration: ClinicalTrials.gov, NCT02426112. Registered on 21 April 2015.
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Background
Respiratory disease is the most common manifestation
of human immunodeficiency virus (HIV)/acquired im-
munodeficiency syndrome (AIDS) among children in
sub-Saharan Africa, accounting for more than 50% of
HIV-associated mortality [1–8]. The use of antiretroviral
therapy (ART) and co-trimoxazole prophylaxis has con-
tributed to a reduction in the rate of acute respiratory
tract infections and mortality among HIV-infected chil-
dren in both high- and low-resource settings [9].
However, studies in recent years in sub-Saharan Africa
have demonstrated that about 30% of perinatally HIV-
infected older children and adolescents have chronic
respiratory symptoms, including chronic cough, reduced
exercise tolerance and significantly impaired lung function
[4, 8]. In these studies, even participants with pronounced
respiratory impairment looked well at rest, and plain
radiological abnormalities were subtle. High-resolution
computed tomography findings showed predominantly
small airway disease consistent with constrictive oblit-
erative bronchiolitis (OB) [4, 10]. Importantly, no asso-
ciation was observed between abnormal lung function,
ART use or duration or CD4 count, suggesting that this
form of HIV-related chronic lung disease may not be
responsive to ART.
OB is a chronic obstructive lung disease that follows a
severe insult to the lower respiratory tract, resulting in
fibrosis of the small airways [11]. The most common
presentation is the post-infectious variant, closely related
to severe viral infection in the first 3 years of life [12]. It
is also seen in the context of allogeneic haematopoietic
stem cell (HSC) and lung transplant recipients as a re-
sult of a graft-versus-host reaction [13, 14]. HIV is asso-
ciated with both high incidence of respiratory infections
and persistent immune activation despite ART [15–17].
Thus, HIV-associated OB may share causal pathways
with both post-infectious and post-transplant variants.
Evidence regarding the efficacy of treatment modal-
ities in OB is sparse. Observational studies have shown
some improvement of lung function in a small number of
children treated with high-dose pulse corticosteroids for
post-transplant OB [14, 18]. Studies in lung transplant-
associated OB have shown a positive effect of azithromy-
cin, whereas a small randomised controlled trial of
patients with established HSC-associated OB failed to
show an effect [19, 20]. Authors of case series including
patients with post-infectious and post-transplant OB have
reported a benefit of azithromycin on lung function and
on rate of exacerbations [21].
Azithromycin is a macrolide antibiotic with bacteriostatic
activity against the most common respiratory bacterial
pathogens. However, it also has a robust immunomodula-
tory effect resulting in decreased production of pro-
inflammatory cytokines in the acute phase and resolution
of chronic inflammation in the later phases. Specific-
ally, azithromycin has direct activity on airway epithe-
lial cells to maintain their function and reduce mucus
secretion [20, 22–24]. These characteristics have re-
sulted in the use of azithromycin in the management of
a variety of chronic lung diseases, including cystic fi-
brosis [25], non-cystic fibrosis bronchiectasis [26],
bronchiolitis obliterans syndrome [19, 27] and chronic
obstructive pulmonary disease [28]. The intracellular
uptake of azithromycin is high, and hepatic excretion is
slow, resulting in a long half-life that enables infrequent
dosing. We will test the hypothesis that prophylactic
azithromycin is effective, through its antimicrobial and
anti-inflammatory properties, in preventing worsening
of lung function and in reducing exacerbations in chil-
dren and adolescents receiving ART who have HIV-
associated chronic lung disease.
Methods/design
Study design
BREATHE (Bronchopulmonary function in response to
azithromycin treatment for chronic lung disease in HIV-
infected children) is a two-site, double-blind, placebo-
controlled, individually randomised trial in which we
intend to enrol 400 perinatally HIV-infected children
and adolescents aged 6–19 years with HIV-associated
chronic lung disease who have been receiving ART for a
minimum of 6 months. Participants will be enrolled
from the outpatient HIV clinics in Harare, Zimbabwe,
and Blantyre, Malawi.
Study intervention
Participants are randomly assigned to receive either azi-
thromycin or placebo in a 1:1 ratio. Weight-band azi-
thromycin (10–19.9 kg, 250 mg; 20–29.9 kg, 500 mg;
30–39.9 kg, 750 mg; > 40 kg, 1250 mg/week) or placebo
will be given weekly under direct observation by a treat-
ment monitor identified within the family for a total of
12 months.
Study population
HIV-infected children and adolescents with HIV-
associated chronic lung disease attending outpatient
HIV clinics in Harare and Blantyre will be enrolled in
the trial. Individuals aged 6–19 years will be approached
together with their guardians during their routine HIV
outpatient visits and provided with information about
the study. Once informed consent is obtained for screen-
ing, eligibility will be established using a multi-step
screening procedure. Chronic lung disease will be estab-
lished by spirometry (forced expiratory volume in 1 sec-
ond [FEV1] z-score less than −1.0) with no reversibility
(< 12% improvement in FEV1 after salbutamol 200 μg in-
haled using a spacer). Spirometry will be performed
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using the EasyOne™ spirometer (ndd Medical Technolo-
gies Inc., Andover, MA, USA) by trained research staff
certified in performing spirometry and following the
American Thoracic Society guidelines. Those who meet
the criteria for chronic lung disease will undergo further
tests, including a urine pregnancy test (for girls who
have reached menarche), serum creatinine, alanine ami-
notransferase (ALT), an electrocardiogram and screening
for tuberculosis (TB). For TB screening, we will use the
Xpert™ MTB/RIF (Cepheid, Sunnyvale, CA, USA) to test
one sputum sample obtained either spontaneously or
through induction.
Inclusion/exclusion criteria
Perinatally HIV-infected children and adolescents aged
6–19 years who have been receiving ART for at least 6
months for HIV-associated chronic lung disease, who
have a firm home address and a stable guardian, and
with consent from the guardian and assent from the par-
ticipant (for those aged < 18 years; those aged ≥ 18 years
to consent independently) will be eligible for inclusion.
Exclusion criteria will include having a condition that
may prove fatal during the study period (e.g., malig-
nancy), TB or acute respiratory tract infection at the
time of screening, pregnancy or breastfeeding, history of
cardiac arrhythmia, a prolonged QTc interval, abnormal
creatinine clearance or elevated ALT, known macrolide
hypersensitivity, and concomitant use of digoxin and/or
fluconazole (or other drugs known to prolong the QTc
interval) (Table 1).
Study procedures
Eligible individuals will be randomised to either azithro-
mycin or placebo. The allocation ratio will be 1:1 by
block randomisation with variable-length blocks strati-
fied by site. The randomisation schedule and allocation
list will be generated using Stata™ version 14 software
(2015 release; StataCorp, College Station, TX, USA) by
an independent statistician not connected with the
study. The allocation list will be sent directly to the
study pharmacists at both trial sites, who will prepare
the study medication. Participants and study personnel
will therefore be masked to treatment allocation. The
pharmacist will be provided with only randomly allo-
cated numbers assigning participants to arm 1 or arm 2,
with each number linked to a study number, and there-
fore the pharmacist will also remain blinded. It will not
be possible to have pre-prepared medication packs,
owing to changes of dose with weight.
After randomisation, spirometry will be repeated, and
cardiopulmonary fitness will be evaluated using the in-
cremental shuttle walk test. Transthoracic echocardiog-
raphy will be performed by a trained echocardiographer
using the SonoSite™ M-Turbo echocardiography system
(FUJIFILM SonoSite, Bothell, WA, USA) at the Malawi
site and the Mindray™ DC-N6 echocardiography system
(Mindray, Shenzhen, China) at the Zimbabwe site to as-
sess right heart function and pulmonary hypertension.
The research nurse will take a rectal swab, nasal aspirate,
and sputum and blood samples. The blood sample will
be used to measure CD4 count with the Pima™ Analyser
(Alere, Orlando, FL, USA) and to perform viral load test-
ing (Xpert™ HIV-1 Viral Load; Cepheid). The study drug
will be dispensed by the study pharmacist. After the en-
rolment visit, follow-up visits will be scheduled at 2
weeks and 3-monthly thereafter. Participants will be
followed for a minimum of 12 months to ascertain the
primary outcome and for a further 6 months (i.e., 6
months following completion of study drug) to investi-
gate durability of effect (if any) of the intervention. Pro-
cedures undertaken at the follow-up visits are
summarised in Fig. 1.
Participants will be instructed to attend unscheduled
visits if they develop acute symptoms. For specific acute
symptoms, investigations and management will be as fol-
lows: for diarrhoeal episodes (Division of AIDS [DAIDS]
severity grade ≥ 3), a rectal swab and Clostridium difficile
rapid test will be taken (C. Diff Quick Check Complete™;
Alere) and if positive will be treated with metronidazole
for 7 days. For acute respiratory exacerbations, sputum
and nasal swabs will be taken and will be treated with
amoxicillin-clavulanate for 10 days; if there is no im-
provement, a chest radiograph and culture for TB will
be obtained. For febrile episodes, blood cultures, malaria
slides and or malaria rapid diagnostic tests and rectal
swabs will be taken, and management will be carried out
according to national guidelines. For other acute symp-
toms, investigations and management will be carried out
at the discretion of the treating clinician. A nasal swab,
rectal swab, and sputum and blood samples will be col-
lected at study visits for measurement of immune activa-
tion markers, investigation of antimicrobial resistance
and assessment of changes in the gut and respiratory
microbiome.
Risks
Potential risks include an allergic reaction or adverse re-
action to the medication or placebo. Examples of poten-
tial side effects include nausea, vomiting, diarrhoea and
skin reactions. Each of these risks and any other unex-
pected outcomes will be monitored at study visits. Cri-
teria for stopping the study drug are allergic reaction,
QTc prolongation > 500 milliseconds, hepatic toxicity
with ALT > 80 IU/L, concomitant use of drugs known to
produce QTc prolongation, pregnancy during the course
of the study and any adverse reaction with DAIDS sever-
ity grade > 3. In case of any serious adverse events, the
institutional review boards and the data and monitoring
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safety board (DSMB) will be notified. Unblinding of
treating physicians will be carried out in case of preg-
nancy or other events after decision by the DSMB.
Outcome measures
The primary outcome is the mean difference between
trial arms in FEV1 z-scores (generated using Global
Lung Function Initiative reference standards) between
trial arms at 12 months after initiation of the study drug,
adjusted for site and baseline FEV1 z-score. The second-
ary outcomes are described in Table 2.
Other outcomes will be the effect of azithromycin on
(1) diversity and composition of respiratory and gut
microbiome of children with HIV-associated chronic
lung disease, (2) antibiotic resistance of bacteria colonis-
ing the respiratory tract, and (3) biomarkers of systemic
inflammation.
Laboratory procedures
Nasopharyngeal and sputum samples will be frozen and
stored at −80 °C for later batch processing, which will
include routine bacterial culture for respiratory patho-
gens, antimicrobial susceptibility testing and 16S riboso-
mal RNA (rRNA) amplicon sequencing (microbiome
analysis). Microbiome analysis of stool samples will also
be done.
Archived plasma samples (isolated and stored at −80 °C)
will be used to quantify the levels of soluble markers of
immune activation and microbial translocation, including
high-sensitivity C-reactive protein, D-dimers, interleukin-
6, β2-microglobulin and soluble CD14 using multiplex
bead assays (Luminex, Austin, TX, USA). Levels of bacter-
ial 16S rRNA will be quantified using qRT-PCR to meas-
ure the extent of microbial translocation over time. The
levels of these markers will be correlated with FEV1 z-
scores and compared between trial arms.
Data collection and management and analysis plan
Research nurses and assistants collect the data at base-
line and follow-up and record it on electronic clinical
record forms using Google Nexus™ tablets (Google,
Mountain View, CA, USA) running OpenDataKit soft-
ware. In both countries, data will be uploaded, processed
and saved to a Microsoft Access database (Microsoft,
Redmond, WA, USA) before being exported to Stata
version 14.0 software and merged into a single database
backed up on a regular basis. Consistency checks and
checks for missing data are performed both at data entry
and fortnightly once the database has been merged. La-
boratory data will be recorded on paper forms and en-
tered into the database using optical character
recognition. Spirometric data will be uploaded directly
from the spirometer. Echocardiographic data will be
Fig. 1 Schedule of trial procedures. ALT Alanine aminotransferase, ECG Echocardiography, HIV Human immunodeficiency virus, TB Tuberculosis
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recorded on electronic clinical record forms, and these
will be processed and saved to the Microsoft Access
database for merging with the main trial database.
The primary analysis will be done on a modified
intention-to-treat basis [29]. Secondary analyses will in-
clude a per-protocol analysis which will be defined using
all adherence data prior to unblinding the study. Con-
tinuous outcomes will be compared between treatment
groups, adjusting for site and baseline measures of the
outcome and using linear regression to estimate the
mean difference and corresponding 95% CI. Time-to-
event outcomes will be assessed using Cox proportional
hazards regression and graphically displayed using
Kaplan-Meier estimates. Between-group comparisons of
binary outcomes will be analysed with logistic regression
to estimate ORs and 95% CIs. Count data (e.g., number
of hospitalisations) will be analysed using Poisson re-
gression to estimate incidence rate ratios and 95% CIs.
All analyses will be adjusted for site. Pre-specified effect
modification analyses will include site and baseline se-
verity of lung disease.
Sample size and power
The following assumptions were made to calculate the
sample size:
 Mean FEV1 z-score of −2.04 in the control group
 Patients randomised in equal proportions to the two
regimens
 Up to 25% of participants unassessable owing to loss
to follow-up, death or suboptimal spirometric traces
 No change in FEV1 z-score in the control arm
 Difference in the trial arm mean FEV1 z-scores
ranging from 0.15 to 0.3, an effect assumed to be
of clinical relevance
 SD ranging from 0.55 to 0.82 to assess the impact of
variability on the difference in mean value the study
has power to detect
Under these assumptions, a sample size of 400 recruited
participants and 300 participants with outcome data (25%
unassessable based on previous studies of Zimbabwean
children) will enable 80% power to detect a difference in
trial arm means ranging between 0.17 and 0.23, an effect
size (difference in means/SD) of 0.32 (Fig. 2).
Ethics and regulatory bodies
The trial will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki, in compliance with
the protocol approved by relevant ethics committees, and
according to good clinical practice standards [30]. No
change in the protocol will be implemented without the
prior review and approval of the regulatory authorities,
except where it may be necessary to eliminate an imme-
diate hazard to the trial participants. Details concerning
the enrolment process can be found in the Standard
Protocol Items: Recommendations for Interventional Tri-
als (SPIRIT) checklist (Additional file 1) [31].
The trial sponsor is the London School of Hygiene
and Tropical Medicine (LSHTM). The trial will be mon-
itored by the Clinical Trials Unit of the LSHTM and ex-
ternally by the University of Zimbabwe Research
Table 2 Secondary outcomes
Outcome Time point
Time to first respiratory exacerbation
Time to death
Number of acute exacerbations By 12 months
Number of hospitalisations By 12 months
Number of mild, moderate and severe
adverse events
By 12 months
Mean weight-for-age z-score adjusted
for baseline
By 12 months
Incidence of infectious episodes
(Salmonella typhi, malaria, gastroenteritis)
By 12 months
Durability of effect (FEV1 z-score) 18 months
FEV1 Forced expiratory volume in 1 second
Table 1 Inclusion/exclusion criteria
Inclusion criteria
• Perinatally acquired HIV (self-report of no sexual debut or blood
transfusions, a history of orphanhood owing to maternal HIV disease
and/or a history of sibling death due to HIV, and characteristic
clinical features (i.e., stunting, history of recurrent minor infections in
childhood and planar warts)
• Aged 6–19 years
• On first- or second-line ART for≥ 6 months
• Chronic lung disease (FEV1 z-score less than −1 and < 12%
improvement with bronchodilator)
• Firm home address accessible in Blantyre/Harare and intending to
remain there for 18 months
• Stable caregiver for participants aged < 18 years
• HIV status disclosed to the child (for those aged > 12 years)
• Informed consent to participate in the trial (for those aged < 18
years, consent from guardian and assent from participant; for those
aged ≥ 18 years, consent from participant)
Exclusion criteria
• Any condition that may prove fatal during the study period
• Diagnosis of tuberculosis at enrolment
• Acute respiratory tract infection during enrolment
• Pregnancy and breastfeeding
• History of prolonged QTc syndrome or current or planned therapy
with drugs likely to cause cardiac dysrhythmias
• History of cholestatic jaundice or hepatic dysfunction associated
with previous use of azithromycin or known hypersensitivity to a
macrolide or ketolide drug
• Prolonged QTc interval (> 440 milliseconds in males; > 460
milliseconds in females)
• Creatinine clearance < 30 ml/minute
• ALT > 80 IU/L
• Concomitant use of digoxin and/or fluconazole
• Lack of understanding of the study procedure or uncooperative
behaviour
Abbreviations: ALT Alanine aminotransferase, ART Antiretroviral therapy, FEV1
Forced expiratory volume in 1 second, HIV Human immunodeficiency virus
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Support Centre in Zimbabwe and the Malawi-Liverpool
Wellcome Trust Clinical Research Programme Clinical
Trials Unit in Malawi.
Publication
Results of this trial will be published on completion in a
peer-reviewed scientific journal. The funder will not be
involved in the analysis or interpretation of the data.
The full anonymised dataset will be made available no
longer than 18 months after completion of the trial.
Discussion
The massive scale-up of ART programmes globally has re-
sulted in a dramatic improvement in survival, such that
increasing numbers of children perinatally infected with
HIV, many of whom would have died in early childhood
without HIV treatment, are now reaching adolescence.
Thus, attention needs to be focused on addressing the
chronic complications of long-standing HIV infection
prevalent among this cohort of older HIV-infected survi-
vors. Studies in recent years have demonstrated a high
burden of chronic lung disease in children with HIV in
sub-Saharan Africa, even among those receiving ART and
virologically suppressed. The urgency with which
evidence-based management guidelines are needed is
starkly apparent: Nearly one-third of older children have
chronic respiratory symptoms, and in the absence of any
alternative therapeutic strategies, repeated treatment for
presumptive TB is the only treatment offered and often
administered. Our group has investigated bronchodilators
and short course, high-dose steroids in patients with
chronic lung disease who are receiving ART and isoniazid
preventive therapy, with no suggestions of benefit (per-
sonal communication, T. Mwalukomo).
Whereas in the pre-ART era, lymphoid interstitial pneu-
monitis (LIP) was the most common cause of chronic
lung disease, studies in the ART era show that OB is the
most likely underlying cause, with LIP being an excep-
tional finding. OB is a potentially life-threatening condi-
tion that can progress to hypoxic respiratory failure and
cor pulmonale and may impair lung growth in children.
OB results from small airway inflammation and subse-
quent fibrosis, and in the context of HIV, it is likely that
inflammation is a consequence of both HIV-mediated
chronic immune activation, resulting in end-organ dam-
age, as well as repeated infections due to HIV-mediated
immunodeficiency. We therefore postulate that azithro-
mycin is a strong candidate as a therapeutic agent for
HIV-associated chronic lung disease, given its broad-
spectrum antibiotic activity and its anti-inflammatory and
immunomodulatory properties, as well as demonstrated
activity in similar chronic lung diseases and a good safety
profile and tolerability. In this trial, we will investigate the
effect of azithromycin on lung function as well as on acute
exacerbations and other infections, and the trial will pro-
vide insight into the pathogenesis of this condition.
Trial status
The current protocol is version 2.2, dated 21 August
2017. Enrolment started in June 2016 and will continue
until June 2018.
Fig. 2 Sample size calculations. FEV1 Forced expiratory volume in 1 second
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Additional file 1: SPIRIT checklist. (DOC 147 kb)
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